Jan. 31 2025
Source Page: Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)Found: Breast cancer (neoadjuvant & OFS): advisory committee – interests register 1 of 16 Breast
Mentions:
1: None support bereaved families and drive vital research in this area—Macmillan, Cancer Research UK, Cancer52 - Speech Link
2: None As Cancer Research UK pointed out in its submission to the investigation, the 62-day target for referral - Speech Link
3: None Cancer Research UK has forecast half a million cancer cases each year by 2040. - Speech Link
4: None , world-leading trial to transform breast cancer care through artificial intelligence. - Speech Link
5: Lord Trefgarne (Con - Excepted Hereditary) I lost my wife of 55 years in April last year due to breast cancer. - Speech Link
Asked by: Sharon Hodgson (Labour - Washington and Gateshead South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what information his Department holds on whether there are ongoing trials to assess whether continuing hormone therapy indefinitely after a primary breast cancer diagnosis would prevent this cohort of patients from going on to develop secondary breast cancer.
Answered by Andrew Gwynne
Research is crucial in tackling cancer, which is why the Department invests over £1.5 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £133 million in 2023/24. Cancer is a major area of NIHR spend, reflecting its high priority. The NIHR has commissioned three current studies relevant to this issue, specifically:
The NIHR's Biomedical Research Centres (BRCs) are networks of experts that work collaboratively between the National Health Service and internationally renowned universities. They facilitate early-stage experimental medicine research and support the translation of scientific discoveries. The BRCs are currently supporting a further two relevant studies:
The NIHR continues to encourage and welcome funding applications for research into any aspect of human health, including cancer. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Mentions:
1: Wera Hobhouse (LD - Bath) cancer than are women over 50.It is truly alarming that in the UK, breast cancer accounts for 43% of - Speech Link
2: Karin Smyth (Lab - Bristol South) The investments we are making now in breast cancer treatment and research are part of our plan to make - Speech Link
3: Karin Smyth (Lab - Bristol South) breast cancer research in the last five years. - Speech Link
Feb. 19 2025
Source Page: Early and locally advanced breast cancer: diagnosis and managementFound: Page 1 of 4 ‘Early and locally advanced breast cancer: diagnosis and management - Lymphoedema
Jan. 31 2025
Source Page: Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update)Found: Early and locally advanced breast cancer: diagnosis and management – Neoadjuvant chemotherapy and ovarian
Apr. 11 2025
Source Page: Early and locally advanced breast cancer: diagnosis and managementFound: BMJ Technology Assessment Group BNMS Bradford District Care Trust Breast Cancer Now Bristol-Myers Squibb
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve (a) diagnosis times and (b) treatment of invasive lobular breast cancer.
Answered by Andrew Gwynne
We will improve cancer survival rates and hit all National Health Service cancer waiting time targets so no patient waits longer than they should.
Improving early diagnosis of cancer, including breast cancer, is a priority for the Government. There are multiple NHS initiatives and funding streams across the NHS in England that support the early detection of breast cancer, and many organisations across the health service are involved.
The Department spends £1.5 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR), with cancer the largest area of spend at more than £121.8 million in 2022/23. NIHR spends more on cancer than any other disease group, reflecting its high priority. Our investments in cancer, including lobular breast cancer, are pivotal to informing efforts to improve cancer prevention, treatment, and outcomes.
We are proud to have invested £29 million into the Institute of Cancer Research (ICR) and the Royal Marsden NIHR Biological Research Centre in 2022, supporting their efforts to strengthen research into cancer, including lobular breast cancer. This is complemented by wider investments into breast cancer research including, for example, a £1.3 million project to determine whether an abbreviated form of breast magnetic resonance imaging can detect breast cancers missed by screening through mammography, again including lobular breast cancer.
The NIHR continues to encourage and welcome applications for research into any aspect of human health, including lobular breast cancer. Applications are subject to peer review and judged in open competition, with awards made based on the importance of the topic to patients and health and care services, value for money and scientific quality.
Feb. 19 2025
Source Page: Early and locally advanced breast cancer: diagnosis and managementFound: g) Sex Breast cancer is a disease that mainly affects women.
Feb. 12 2025
Source Page: Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapyFound: Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy